Spinal Cord
Conditions
Brief summary
To learn if MRS can effectively assess spinal cord lesions.
Detailed description
Primary Objective: Establish the feasibility and spectrum of MRS for adult patients while mapping the total spine spectrum at short TEs to allow for future comparison with patients to assess spinal cord lesions malignant potential and grade. Secondary Objective: Test success of the spectrum by implementing the protocol on 3 low volume LMD receiving LMD receiving CSI. This will allow us to test reproducibility of the protocol and test effect of radiation on spinal cord at different time frames. This will serve as secondary data for subsequent trials targeting functional statues after radiation and tumor grading predictability of MRS.
Interventions
Participants will receive MRS Scan
Sponsors
Study design
Eligibility
Inclusion criteria
Volunteers: * Adults \> 18 years * Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions. * Consent able patients. Patients with low volume LMD to receive treatment CNS radiation: * Adults \> 18 years old. * MR or CSF with evidence of LMD. * Patients to receive CSI as part of standard treatment of LMD disease. * Consent able patients, willingness and ability to comply with the study procedures. * No spinal cord lesions only LMD disease * Recruitment by radiation oncology faculty in consultation with Dr. De. . .
Exclusion criteria
Volunteers: * Age \< 18 years * Pregnant or breastfeeding individuals. * History of cancer. * History of spinal cord lesions including malignant, demyelinating, or inflammatory. * History of prior spinal surgery. * History of implantable devices. * History of MR claustrophobia. * Degenerative disease or spinal/back pain including myelopathy and radiculopathy. * Scoliosis. Patients with LMD: * Age \< 18 years * History of spinal cord lesions including malignant, demyelinating, or inflammatory. * History of prior spinal surgery. * History of implantable devices. * History of MR claustrophobia. * Degenerative disease or spinal/back pain including myelopathy and radiculopathy. * Scoliosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Adverse Events (AEs) | Through study completion; an average of 1 year. | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) |
Countries
United States
Contacts
M.D. Anderson Cancer Center